At the very least 4 prime pharmaceutical firms suing the federal authorities over a brand new requirement to barter Medicare drug costs have agreed to come back to the desk for the primary spherical of negotiations—no less than for now.
Merck, AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim have all stated that they are going to comply with the negotiations, although some have been clearly bitter about it.
The 4 firms manufacture pharmaceuticals that have been among the many first 10 chosen by Division of Well being and Human Providers to be topic to cost negotiations, a provision beneath the Biden administration’s Inflation Discount Act. Particularly, Merck makes the Kind 2 diabetes drug Januvia, AstraZeneca is behind the diabetes drug Farxiga, Boehringer Ingelheim makes the diabetes drug Jardiance, and Bristol Myers Squibb makes Eliquis, a drug for blood clotting—all of which have been chosen for drug negotiations.
Learn 12 remaining paragraphs | Feedback